The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis

Atulya (Atul) Deodhar, Bojena Bitman, Yue Yang, David H. Collier

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease (CVD). Treatment with tumor necrosis factor inhibitors improves both joint symptoms associated with RA and also CVD risk. This exploratory analysis of a phase 4 study evaluated changes in metabolic risk factors in patients with RA treated with etanercept. Metabolic analytes were measured at baseline, week 12, and week 24 in patients enrolled in a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in moderately active RA. Patients received either placebo or etanercept 50 mg every week (QW) for 12 weeks, after which all patients received etanercept 50 mg QW through week 24. Levels of metabolic analytes were assessed in all patients, including patients with diabetes and hyperlipidemia, and described descriptively. A total of 210 patients were randomized, 104 to placebo and 106 to etanercept. There were no significant changes in metabolic risk factors from baseline to week 12 or 24 in all patients. Levels of metabolic analytes were similar in patients with diabetes and hyperlipidemia, with some exceptions; fasting glucose and fasting insulin decreased through week 12, and hemoglobin A1C decreased slightly through week 24 in patients with diabetes. Treatment with etanercept did not adversely affect levels of metabolic risk factors for CVD in patients with RA.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalClinical Rheumatology
DOIs
StateAccepted/In press - Oct 5 2016

Fingerprint

Rheumatoid Arthritis
Cardiovascular Diseases
Placebos
Hyperlipidemias
Etanercept
Fasting
Hemoglobins
Tumor Necrosis Factor-alpha
Joints
Insulin
Safety
Glucose
Therapeutics

Keywords

  • Cardiovascular disease
  • Rheumatoid arthritis
  • Tumor necrosis factor inhibitor

ASJC Scopus subject areas

  • Rheumatology

Cite this

The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis. / Deodhar, Atulya (Atul); Bitman, Bojena; Yang, Yue; Collier, David H.

In: Clinical Rheumatology, 05.10.2016, p. 1-8.

Research output: Contribution to journalArticle

@article{14b6eeadbcac41248001f89c27de95fd,
title = "The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis",
abstract = "Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease (CVD). Treatment with tumor necrosis factor inhibitors improves both joint symptoms associated with RA and also CVD risk. This exploratory analysis of a phase 4 study evaluated changes in metabolic risk factors in patients with RA treated with etanercept. Metabolic analytes were measured at baseline, week 12, and week 24 in patients enrolled in a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in moderately active RA. Patients received either placebo or etanercept 50 mg every week (QW) for 12 weeks, after which all patients received etanercept 50 mg QW through week 24. Levels of metabolic analytes were assessed in all patients, including patients with diabetes and hyperlipidemia, and described descriptively. A total of 210 patients were randomized, 104 to placebo and 106 to etanercept. There were no significant changes in metabolic risk factors from baseline to week 12 or 24 in all patients. Levels of metabolic analytes were similar in patients with diabetes and hyperlipidemia, with some exceptions; fasting glucose and fasting insulin decreased through week 12, and hemoglobin A1C decreased slightly through week 24 in patients with diabetes. Treatment with etanercept did not adversely affect levels of metabolic risk factors for CVD in patients with RA.",
keywords = "Cardiovascular disease, Rheumatoid arthritis, Tumor necrosis factor inhibitor",
author = "Deodhar, {Atulya (Atul)} and Bojena Bitman and Yue Yang and Collier, {David H.}",
year = "2016",
month = "10",
day = "5",
doi = "10.1007/s10067-016-3422-7",
language = "English (US)",
pages = "1--8",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

TY - JOUR

T1 - The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis

AU - Deodhar, Atulya (Atul)

AU - Bitman, Bojena

AU - Yang, Yue

AU - Collier, David H.

PY - 2016/10/5

Y1 - 2016/10/5

N2 - Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease (CVD). Treatment with tumor necrosis factor inhibitors improves both joint symptoms associated with RA and also CVD risk. This exploratory analysis of a phase 4 study evaluated changes in metabolic risk factors in patients with RA treated with etanercept. Metabolic analytes were measured at baseline, week 12, and week 24 in patients enrolled in a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in moderately active RA. Patients received either placebo or etanercept 50 mg every week (QW) for 12 weeks, after which all patients received etanercept 50 mg QW through week 24. Levels of metabolic analytes were assessed in all patients, including patients with diabetes and hyperlipidemia, and described descriptively. A total of 210 patients were randomized, 104 to placebo and 106 to etanercept. There were no significant changes in metabolic risk factors from baseline to week 12 or 24 in all patients. Levels of metabolic analytes were similar in patients with diabetes and hyperlipidemia, with some exceptions; fasting glucose and fasting insulin decreased through week 12, and hemoglobin A1C decreased slightly through week 24 in patients with diabetes. Treatment with etanercept did not adversely affect levels of metabolic risk factors for CVD in patients with RA.

AB - Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease (CVD). Treatment with tumor necrosis factor inhibitors improves both joint symptoms associated with RA and also CVD risk. This exploratory analysis of a phase 4 study evaluated changes in metabolic risk factors in patients with RA treated with etanercept. Metabolic analytes were measured at baseline, week 12, and week 24 in patients enrolled in a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in moderately active RA. Patients received either placebo or etanercept 50 mg every week (QW) for 12 weeks, after which all patients received etanercept 50 mg QW through week 24. Levels of metabolic analytes were assessed in all patients, including patients with diabetes and hyperlipidemia, and described descriptively. A total of 210 patients were randomized, 104 to placebo and 106 to etanercept. There were no significant changes in metabolic risk factors from baseline to week 12 or 24 in all patients. Levels of metabolic analytes were similar in patients with diabetes and hyperlipidemia, with some exceptions; fasting glucose and fasting insulin decreased through week 12, and hemoglobin A1C decreased slightly through week 24 in patients with diabetes. Treatment with etanercept did not adversely affect levels of metabolic risk factors for CVD in patients with RA.

KW - Cardiovascular disease

KW - Rheumatoid arthritis

KW - Tumor necrosis factor inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84990842022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990842022&partnerID=8YFLogxK

U2 - 10.1007/s10067-016-3422-7

DO - 10.1007/s10067-016-3422-7

M3 - Article

C2 - 27704313

AN - SCOPUS:84990842022

SP - 1

EP - 8

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -